gemcitabine has been researched along with olaparib in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (68.75) | 24.3611 |
| 2020's | 5 (31.25) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Afratis, K; Gavras, H; Karamanos, NK; Koutsakis, C; Leonardi, S; Papaioannou, D; Piperigkou, Z; Rassias, G; Rigopoulou, D; Vachlioti, E | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Carter, CA; Figg, WD; Giaccone, G; Gutierrez, M; Ji, J; Kelly, RJ; Kummar, S; Mannargudi, B; Rajan, A; Spencer, S; Szabo, E; Woo, S; Yancey, MA | 1 |
| Bhalla, A; Saif, MW | 1 |
| Azim, HA; de Azambuja, E; Piccart, M; Sonnenblick, A | 1 |
| Bendell, J; Burke, W; Burris, H; Chau, I; Fielding, A; Hochster, H; Middleton, MR; O'Reilly, EM | 1 |
| Matsumoto, K; Onda, T; Yaegashi, N | 1 |
| Andersson, BS; Champlin, RE; Li, Y; Liu, Y; Murray, D; Nieto, Y; Valdez, BC | 1 |
| Algül, H; Azoitei, N; Bohnenberger, H; Frappart, PO; Gaedcke, J; Gieldon, L; Hampp, S; Hessmann, E; Hohwieler, M; Ihle, M; Kleger, A; Lechel, A; Lesina, M; Liebau, S; Lin, Q; Perkhofer, L; Reinhardt, HC; Romero Carrasco, MC; Ruess, DA; Russell, R; Schmitt, A; Schröck, E; Seufferlein, T; Sipos, B; Wagner, M; Wiesmüller, L | 1 |
| Dai, H; Guo, S; Jiang, Y; Li, Y; Lin, SY; McGrail, DJ; Yin, J | 1 |
| Anderson, GJ; Du, C; Han, X; Lang, J; Min, H; Nie, G; Qi, Y; Qin, H; Shi, Q; Tian, X; Wang, Y; Yang, Y; Zhang, Y; Zhang, Z; Zhao, X; Zhao, Y | 1 |
| Arcieri, M; Ergasti, R; Fagotti, A; Marchetti, C; Palluzzi, E; Pietragalla, A; Rosati, A; Scaletta, G; Scambia, G | 1 |
| Cepero, A; Martin-Guerrero, SM; Martin-Oliva, D; Melguizo, C; Munoz-Gamez, JA; Ortiz, R; Prados, J; Quinonero, F; Urbano, D | 1 |
| Amé, JC; Burckel, H; Mura, C; Noël, G; Waissi, W | 1 |
| Jiménez-Luna, C; Melguizo, C; Mesas, C; Muñoz-Gámez, JA; Ortiz, R; Perazzoli, G; Prados, J; Quiñonero, F | 1 |
2 review(s) available for gemcitabine and olaparib
| Article | Year |
|---|---|
An update on PARP inhibitors--moving to the adjuvant setting.
Topics: Adjuvants, Pharmaceutic; Antineoplastic Agents; Benzamides; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Carboplatin; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Breaks, Single-Stranded; DNA Repair; Female; Gemcitabine; Humans; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors | 2015 |
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids | 2015 |
2 trial(s) available for gemcitabine and olaparib
| Article | Year |
|---|---|
A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases | 2012 |
Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Pancreatic Neoplasms; Phthalazines; Piperazines; Prognosis; Survival Rate | 2015 |
12 other study(ies) available for gemcitabine and olaparib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
Topics: Anti-Bacterial Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Quinolines; Receptor, Bradykinin B2 | 2021 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
PARP-inhibitors in BRCA-associated pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Mutation; Pancreatic Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Survival Analysis; Treatment Outcome | 2014 |
The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; DNA Damage; DNA Repair; Drug Synergism; Gemcitabine; Humans; Lymphoma; Male; Melphalan; Middle Aged; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Reactive Oxygen Species; Tumor Cells, Cultured | 2017 |
ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Pancreatic Ductal; Deoxycytidine; DNA Damage; Fluorouracil; Gemcitabine; Gene Expression; Genomic Instability; Humans; Immunohistochemistry; Male; Mice; Mice, SCID; Pancreatic Neoplasms; Phthalazines; Piperazines | 2017 |
PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; DNA Damage; Drug Synergism; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Recombinational DNA Repair; Xenograft Model Antitumor Assays | 2019 |
Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 ( BRCA2) Mutation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA2 Protein; Deoxycytidine; Drug Delivery Systems; ErbB Receptors; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Nanoparticles; Neoplasms, Experimental; Pancreatic Neoplasms; Peptides; Phthalazines; Piperazines | 2018 |
Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines | 2019 |
Identification of PARP-1 in cancer stem cells of gastrointestinal cancers: A preliminary study.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Colonic Neoplasms; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Irinotecan; Liver Neoplasms; Mice; Neoplastic Stem Cells; Pancreatic Neoplasms; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Xenograft Model Antitumor Assays | 2021 |
Gemcitabine-Based Chemoradiotherapy Enhanced by a PARP Inhibitor in Pancreatic Cancer Cell Lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Gemcitabine; Histones; Humans; Pancreatic Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Radiation-Sensitizing Agents | 2021 |
PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcitabine.
Topics: Antineoplastic Agents; Cell Line, Tumor; Gemcitabine; Humans; Pancreatic Neoplasms; Poly (ADP-Ribose) Polymerase-1; Xenograft Model Antitumor Assays | 2022 |